Fig.4From: Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney diseaseNetwork meta-analysis reporting RR for MACE in patients with T2DM and CKDBack to article page